磁共振影像组学预测脑胶质瘤MGMT启动子甲基化状态的研究进展  

Research progress of magnetic resonance radiomics in predicting the methylation status of MGMT promoter in glioma

作　　者：李鼎 王效春[2] LI Ding;WANG Xiaochun(College of Medical Imaging,Shanxi Medical University,Taiyuan 030001,China;Department of Radiology,First Hospital of Shanxi Medical University,Taiyuan 030001,China)

机构地区：[1]山西医科大学医学影像学院,太原030001 [2]山西医科大学第一医院影像科,太原030001

出　　处：《磁共振成像》2023年第12期146-150,171,共6页Chinese Journal of Magnetic Resonance Imaging

基　　金：国家自然科学基金(编号:81971592)。

摘　　要：脑胶质瘤是最常见的原发恶性中枢神经系统(central nervous system,CNS)肿瘤,约占CNS原发恶性肿瘤的75%,且预后较差。替莫唑胺(temozolomide,TMZ)作为脑胶质瘤化疗一线药物,其治疗敏感性与O6-甲基鸟嘌呤-DNA甲基转移酶(O6-methylguanine-DNA methyltransferase,MGMT)甲基化状态密切相关。目前检测MGMT启动子甲基化状态主要基于焦磷酸测序,此活检取样耗时长,并且会受肿瘤异质性的影响。近年来,MRI影像组学以及深度学习(deep learning,DL)都得到了极大的发展,其高通量的数据挖掘在一定程度上克服了肿瘤异质性的影响。本文就MRI影像组学和基于DL的MRI影像组学的最新研究进展及其局限性展开综述,旨在为后续的相关研究拓展思路,从而更好地实现脑胶质瘤患者的个性化精准诊疗。Glioma,accounting for approximately 75%of primary malignant tumors in the central nervous system(CNS),is the most common primary malignant CNS tumor and is associated with a poor prognosis.Temozolomide(TMZ)is a first-line chemotherapy drug used for glioma treatment,and its effectiveness is closely linked to the methylation status of O6-methylguanine-DNA methyltransferase(MGMT).Currently,the detection of MGMT promoter methylation status primarily relies on pyrosequencing,which is time-consuming and susceptible to tumor heterogeneity.In recent years,MRI radiomics and deep learning(DL)have been greatly developed,and the high-throughput data mining approach has partially addressed the issue of tumor heterogeneity.This article provides a review of the latest research progress and limitations of MRI radiomics and DL-based MRI radiomics,with the aim to inspire further research in order to achieve personalized and precise diagnosis and treatment for glioma patients.

关 键 词：脑胶质瘤 O6-甲基鸟嘌呤-DNA甲基转移酶 磁共振成像 影像组学 深度学习 替莫唑胺 

分 类 号：R445.2[医药卫生—影像医学与核医学] R730.264[医药卫生—诊断学]